Abstract
Introduction
Although the process of antibody caninisation is now becoming more widely used, it is still a 166 time-consuming method (Gearing et al., 2013) . Also, producing mAbs exclusively for one 167 animal species may not be always commercially viable, and may impede further 168 developments of new candidates. This is clearly illustrated by the fact that while there are 169 now tens of monoclonal antibodies approved worldwide for cancer therapy in humans 170 (Modjtahedi et al., 2012; Reichert, 2012; Ecker et al., 2015) , in veterinary oncology, 171 however, therapeutic antibodies are only just reaching the market (USDA, 2016) .
173
The use of antibodies that have been developed for human therapy in animals is an 174 attractive approach. Some groups have explored the potential use of human mAbs in dogs.
175
Stein and colleagues, for instance, successfully tested an anti-human leukocyte antigen DR in 176 dogs. While it was then concluded that dogs were validated as good models for the trial of an 177 antibody, the authors also note how the study and the patients would have benefited from a 178 species-specific antibody (Impellizeri et al., 2006; Stein et al., 2011; Biller et al., 2014) . was never directly compared to a 'caninised' version of the antibody (Jeglum, 1996 (Jeglum, , 2009 ).
187
Possible side effects were occasionally observed, including facial oedema, erythema, fever, 188 pruritus, vomiting and/or diarrhoea, joint pain and myalgia. Although the antibody seemed to provide clinical benefits, it is possible that its murine origin was part of the reasons why it 190 was later discontinued (Jeglum, 1996 (Jeglum, , 2009 Much more likely to be successful is the interchange of therapeutic antibodies 193 between dogs and cats, for instance. Fc receptors, which are crucial for antibody half-life and 194 effector functions, are very similar between these two domestic species (tested using Ensembl 195 Genome Browser and ClustalOmega 4 ) (Lobo et al., 2004; Strietzel et al., 2014 Anti-mAb reactions may cause CRS and influenza-like symptoms in humans
296
( McLaughlin et al., 1998; Hansel et al., 2010) . In dogs, the murine mAb 231 caused clinical 297 signs such as oedema and fever, but the occurrence of these signs did not impede subsequent 298 administration of the treatment; however, the dogs were preventively treated with 299 antihistamine, corticosteroids and the rate of infusion was reduced (Jeglum, 1996) . It must be 300 noted that side effect management and mAb treatment withdrawal should be considered on a importance of full speciation seems to be to reduce "marked" anti-antibody responses. When 319 reactions do occur against speciated mAbs, these tend to be "tolerable" or "negligible"
320
( Hwang and Foote, 2005) .
The most common signs that follow the rapid infusion of rituximab, a human chimeric Ledermann et al., 1988; Weiden et al., 1994; Dhingra et al., 1995 
Hurdles and opportunities

395
The hurdles and opportunities in the study and production of new antibodies for 396 veterinary use are discussed below and are summarised in Table 3 .
398
The immunogenicity of therapeutic molecules, including monoclonal antibodies, be followed in the future for the production of antibodies (Daniell et al., 2001; Farid, 2007) .
411
This highlights the importance of better understanding the possibilities of using single-dose non-speciated mAbs, which are substantially cheaper to produce, since the price of 413 production will likely hinder the market accessibility of the veterinary biologics industry. 
Conclusions
451
The current trend of biological therapeutics is now reaching veterinary medicine.
452
While there are still many challenges to overcome in order to achieve commercial viability Table 2 909
Potential targets in domestic animal species for monoclonal antibodies in oncology. No longer USDA licensed (Steplewski et al., 1987; Jeglum, 1996 Jeglum, , 2009 USDA, 2016) VEGF ( by Nexvet/Zenoaq None described (Maekawa et al., 2014 (Maekawa et al., , 2016 Nexvet, 2016) Hurdles Opportunities
Immunogenicity of human and mouse mAbs in dogs Caninised and chimeric mAbs
Cost of production of conventional mAbs, with cumulative doses
Alternative mAb production systems and the use of nonspeciated single-dose mAbs. Possible expression systems:
Insect and yeast cells, transgenic plants and animals. Bacterial production of scFv
Difficult tumour penetration
In vivo production of the antibody by the host, through viral transduction or direct DNA injection; use of scFv antibody fragments
Weak results in vivo following promising results in mice
Use of naturally occurring cancers in animals as models to study the therapies is identical to that of the therapeutic mAb (Ab1).
